Discover how menin-KMT2A inhibitors are revolutionizing treatment for aggressive blood cancers with KMT2A rearrangements and NPM1 mutations.
Discover how MS2133, the first DOT1L PROTAC degrader, is revolutionizing leukemia treatment by targeting both enzymatic and scaffolding functions of DOT1L.